Probatebeta
Target

PDE4D

3',5'-cyclic-AMP phosphodiesterase 4D

As of the edition of 20 October 2026, PDE4D (3',5'-cyclic-AMP phosphodiesterase 4D, UniProt Q08499) has 26 drugs tested at it and 22 companies on the list, 7 on route A and 6 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q08499
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
122
Disease areas
Skin and connective tissue; Lungs and airways; Immune system; Inherited and neonatal; Bones, joints and muscles; Nervous system; Infections; Nutrition and metabolism
Registered trials of its drugs
449

Drugs at this target

StatusCount
Marketed12
Active2
Went quiet8
Stopped3
Status not established1
Total26
DrugStatusFurthest phaseUS protection
ApremilastMarketedPhase 4Ends 2028
RoflumilastMarketedPhase 4none listed
Theophylline anhydrousMarketedPhase 4none listed
CrisaboroleMarketedPhase 4Ends 2029
EnsifentrineMarketedPhase 3Ends 2031
IbudilastMarketedPhase 3none listed
DifamilastMarketedPhase 3Ends 2036
TranimilastStoppedPhase 3none listed
ZatolmilastActivePhase 3none listed
GSK-256066Went quietPhase 2none listed
TetomilastStoppedPhase 3none listed
LotamilastWent quietPhase 2none listed

12 of 26 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A7
Route B6
Engaged6
Undetermined3
Total on the list22
Three companies on route A or B, with the route only
CompanyRoute
Chiesi FarmaceuticiRoute A
AstraZenecaRoute B
AmgenRoute B

The other 19 companies at PDE4D

In the product

22 companies in all; 19 are not named here, and no score is.

See the 22 companies at PDE4D, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at PDE4D

Other targets in skin and connective tissue

Companies holding approvals at PDE4D